New drug aims to ease daily struggles of myasthenia gravis
NCT ID NCT07673627
First seen Jun 29, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study tests an experimental drug called empasiprubart in people with a specific type of generalized myasthenia gravis (gMG) who have AChR antibodies. The goal is to see if the drug is safe and can improve symptoms like muscle weakness that affect daily activities. Participants receive either empasiprubart or a placebo by intravenous infusion, and researchers track side effects and changes in symptom scores over 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- empasiprubart
- What this could lead to
- If successful, this could offer a new treatment option for people with generalized myasthenia gravis, potentially improving daily function and quality of life.
- What could go wrong
- This is an early Phase 2a study with only 40 participants, so results may not apply to all patients. The drug may cause side effects or fail to show clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHR-AB SEROPOSITIVE GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Erlanger Health System
RECRUITINGChattanooga, Tennessee, 37403-2136, United States
-
Visionary Investigators Network
RECRUITINGMiami, Florida, 33176-2148, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking daily life unlock myasthenia gravis mysteries?
- Hidden toll of myasthenia gravis: study probes sexual and bladder problems often overlooked
- Engineered immune cells take aim at autoimmune diseases
- Real-World study tracks Efgartigimod's impact on myasthenia gravis symptoms
- New drug MTM-H-001 targets B-Cell autoimmune diseases in early trial
- New drug trial aims to ease muscle weakness in rare disease